Results 21 to 30 of about 63,989 (248)
Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy. [PDF]
, 2017 We present the case of a patient with a deep vein thrombosis (DVT) who failed rivaroxaban therapy. Our patient initially presented with left lower extremity edema, erythema, and pain.
Adashek, Jacob +6 more
core +5 more sources
Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation [PDF]
, 2013 OBJECTIVE: In clinical trials of dabigatran and rivaroxaban for stroke prevention in atrial fibrillation (AF), drug eligibility and dosing were determined using the Cockcroft-Gault equation to estimate creatine clearance as a measure of renal function ...
Ashman, N +6 more
core +2 more sources
BMC Pharmacology and Toxicology, 2020 Background Rivaroxaban, a novel oral anticoagulant drug, is widely used in clinical practice. There is no standardized laboratory monitoring for rivaroxaban, and its plasma concentration in Chinese patients with deep vein thrombosis is unclear.
Ying Li +4 more
doaj +1 more source
Blood, 2022 Venous thromboembolism (VTE) is a common adverse event following surgery, with risks related to the nature of the surgery, the presence of cancer, and other comorbidities.
C. Becattini +25 more
semanticscholar +1 more source
Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events [PDF]
, 2018 Five patients with paroxysmal nocturnal haemoglobinuria and thrombotic complications under oral antithrombotic treatment with vitamin K antagonist were switched to receive the direct oral anticoagulant rivaroxaban an factor Xa inhibitor.
Cafolla, Arturo +4 more
core +1 more source
Rivaroxaban and Hemostasis in Emergency Care
Emergency Medicine International, 2014 Rivaroxaban is an oral, direct Factor Xa inhibitor, approved for the prevention and treatment of several thromboembolic disorders. Rivaroxaban does not require routine coagulation monitoring and has a short half-life. However, confirmation of rivaroxaban
Jürgen Koscielny, Edita Rutkauskaite
doaj +1 more source
Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation? [PDF]
, 2018 © 2018 Bentham Science PublishersBACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.
Akhtar, Zaki +3 more
core +2 more sources
Rivaroxaban for Thromboprophylaxis in High‐Risk Ambulatory Patients with Cancer
New England Journal of Medicine, 2019 BACKGROUND Ambulatory patients receiving systemic cancer therapy are at varying risk for venous thromboembolism. However, the benefit of thromboprophylaxis in these patients is uncertain. METHODS In this double‐blind, randomized trial involving high‐risk
A. Khorana +21 more
semanticscholar +1 more source
JACC: Cardiovascular Interventions, 2022 OBJECTIVES The aim of this study was to investigate the effects of rivaroxaban on left ventricle thromboprophylaxis in patients with anterior ST-segment elevation myocardial infarction (STEMI).
Zhongfan Zhang +12 more
semanticscholar +1 more source